This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fowler, M. B. Search for Related Content PubMed PubMed Citation Articles by Fowler, M. B.

Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs

Michael B. Fowler, MB, FRCP^*, Montserrat Vera-Llonch, MD, MPH, Gerry Oster, PhD, Michael R. Bristow, MD, PhD, FACC, Jay N. Cohn, MD, FACC^||, Wilson S. Colucci, MD, FACC^¶, Edward M. Gilbert, MD, FACC^#, Mary Ann Lukas, MD, FACC^**, Michael J. Lacey, MS^**, Randel Richner, RN^**, Sarah T. Young, PhD^**, Milton Packer, MD, FACC for the U.S. Carvedilol Heart Failure Study Group

^* Division of Cardiovascular Medicine, Stanford University Medical Center, Palo Alto, California, USA
Policy Analysis Inc., Brookline, Massachusetts, USA
Columbia Presbyterian Medical Center, New York, New York, USA
University of Colorado Health Sciences Center, Denver, Colorado, USA
^|| University of Minnesota Medical School, Minneapolis, Minnesota, USA
^¶ Boston University School of Medicine, Boston, Massachusetts, USA
^# University of Utah School of Medicine, Salt Lake City, Utah, USA
^** SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, USA

View larger version (20K): [in a new window]   Figure 1 Combined risk of death or hospitalization for any cause, analyzed using time to the first event. Carv = carvedilol; Plac = placebo.

View larger version (16K): [in a new window]   Figure 2 Hospitalizations during initiation of therapy. The white bar represents placebo-treated patients and the solid bar carvedilol-treated patients.